139 related articles for article (PubMed ID: 1688514)
1. Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i.v. bolus administration of thio-TEPA in ovarian cancer patients.
Hagen B; Neverdal G; Walstad RA; Nilsen OG
Cancer Chemother Pharmacol; 1990; 25(4):257-62. PubMed ID: 1688514
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects.
Hagen B
Cancer Chemother Pharmacol; 1991; 27(5):373-8. PubMed ID: 1705489
[TBL] [Abstract][Full Text] [Related]
3. Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma.
Hagen B; Walseth F; Walstad RA; Iversen T; Nilsen OG
Cancer Chemother Pharmacol; 1987; 19(2):143-8. PubMed ID: 3105905
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of thio-TEPA at two different doses.
Hagen B; Walstad RA; Nilsen OG
Cancer Chemother Pharmacol; 1988; 22(4):356-8. PubMed ID: 3139316
[TBL] [Abstract][Full Text] [Related]
5. Metabolism and alkylating activity of thio-TEPA in rat liver slice incubation.
Hagen B; Dale O; Neverdal G; Azri S; Nilsen OG
Cancer Chemother Pharmacol; 1991; 28(6):441-7. PubMed ID: 1718615
[TBL] [Abstract][Full Text] [Related]
6. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.
Cohen BE; Egorin MJ; Kohlhepp EA; Aisner J; Gutierrez PL
Cancer Treat Rep; 1986 Jul; 70(7):859-64. PubMed ID: 2424593
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Br J Clin Pharmacol; 2009 Jan; 67(1):50-60. PubMed ID: 19076156
[TBL] [Abstract][Full Text] [Related]
8. N,N',N''-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents.
Ng SF; Waxman DJ
Cancer Res; 1991 May; 51(9):2340-5. PubMed ID: 1707751
[TBL] [Abstract][Full Text] [Related]
9. Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography.
van Maanen RJ; van Ooijen RD; Zwikker JW; Huitema AD; Rodenhuis S; Beijnen JH
J Chromatogr B Biomed Sci Appl; 1998 Nov; 719(1-2):103-12. PubMed ID: 9869370
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.
Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
Br J Clin Pharmacol; 2001 Jan; 51(1):61-70. PubMed ID: 11167666
[TBL] [Abstract][Full Text] [Related]
11. Dosing of thioTEPA for myeloablative therapy.
Przepiorka D; Madden T; Ippoliti C; Estrov Z; Dimopoulos M
Cancer Chemother Pharmacol; 1995; 37(1-2):155-60. PubMed ID: 7497586
[TBL] [Abstract][Full Text] [Related]
12. A search for new metabolites of N,N',N''-triethylenethiophosphoramide.
van Maanen MJ; Tijhof IM; Damen JM; Versluis C; van den Bosch JJ; Heck AJ; Rodenhuis S; Beijnen JH
Cancer Res; 1999 Sep; 59(18):4720-4. PubMed ID: 10493531
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.
O'Dwyer PJ; LaCreta F; Nash S; Tinsley PW; Schilder R; Clapper ML; Tew KD; Panting L; Litwin S; Comis RL
Cancer Res; 1991 Nov; 51(22):6059-65. PubMed ID: 1933869
[TBL] [Abstract][Full Text] [Related]
14. Cellular pharmacology of N,N',N''-triethylene thiophosphoramide.
Miller B; Tenenholz T; Egorin MJ; Sosnovsky G; Rao NU; Gutierrez PL
Cancer Lett; 1988 Aug; 41(2):157-68. PubMed ID: 3135933
[TBL] [Abstract][Full Text] [Related]
15. Influence of the tissue distribution of ThioTEPA and its metabolite, TEPA, on the response of murine colon tumours.
Bibby MC; McDermott BJ; Double JA; Phillips RM; Loadman PM; Burgess L
Cancer Chemother Pharmacol; 1987; 20(3):203-6. PubMed ID: 2445497
[TBL] [Abstract][Full Text] [Related]
16. Phase I/pharmacokinetic reevaluation of thioTEPA.
O'Dwyer PJ; LaCreta F; Engstrom PF; Peter R; Tartaglia L; Cole D; Litwin S; DeVito J; Poplack D; DeLap RJ
Cancer Res; 1991 Jun; 51(12):3171-6. PubMed ID: 1710167
[TBL] [Abstract][Full Text] [Related]
17. ThioTEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80.
Masters JR; McDermott BJ; Jenkins WE; Fenwick E; Shah PJ; Mundy AR; Loadman PM; Bibby MC
Cancer Chemother Pharmacol; 1990; 25(4):267-73. PubMed ID: 1688515
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous determination of thioTEPA, TEPA and a novel, recently identified thioTEPA metabolite, monochloroTEPA, in urine using capillary gas chromatography.
van Maanen MJ; Smits KD; Beijnen JH
J Chromatogr B Biomed Sci Appl; 2000 Jun; 742(2):335-43. PubMed ID: 10901138
[TBL] [Abstract][Full Text] [Related]
19. Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.
van Maanen MJ; Huitema AD; Rodenhuis S; Beijnen JH
Anticancer Drugs; 2001 Jul; 12(6):519-24. PubMed ID: 11459998
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of N,N',N''-triethylenethiophosphoramide: oxidative desulfuration to yield N,N',N''-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase.
Ng SF; Waxman DJ
Cancer Res; 1990 Feb; 50(3):464-71. PubMed ID: 2105156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
